Policy· June 30, 2026 · 17 min read
IRA Medicare Drug Negotiation Proposed Rule: Market-Access Analysis
By Ran Chen#IRA Negotiation#CMS#Market Access
Topic
Medicare Part D
Part D formulary design, IRA negotiated prices, out-of-pocket caps, LIS/Extra Help, and Medicare drug coverage policy.
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Policy· June 21, 2026 · 7 min read
Sitagliptin's May 2026 Generic Launch and Januvia's IRA MFP Termination
Pricing & Access· June 9, 2026 · 10 min read
Awiqli coverage guide: insulin icodec access, PA criteria, and Part D pricing
Policy· June 9, 2026 · 12 min read
IRA Medicare drug negotiation third cycle: 15 drugs selected for 2028
Pricing & Access· June 6, 2026 · 10 min read
GLP-1 pharmacy vs medical benefit: routing, cost-sharing, and PA impact
By Ran Chen#GLP-1#Pharmacy Benefit#Medical Benefit
Pricing & Access· June 6, 2026 · 12 min read
Humana GLP-1 coverage: PA criteria, formulary tiers, and 2026 plan rules
By Ran Chen#GLP-1#Prior Authorization#Payer Coverage
Pricing & Access· June 6, 2026 · 12 min read
Medicare Part D GLP-1 coverage 2026: Bridge program, $2,100 cap, and indications
By Ran Chen#GLP-1#Medicare Part D#Prior Authorization
Pricing & Access· June 5, 2026 · 15 min read
Rybelsus coverage guide: oral semaglutide access, formulary tiers, and prior authorization
By Ran Chen#GLP-1#Payer Coverage#Prior Authorization
Policy· June 4, 2026 · 13 min read
Medicare Part D GLP-1 coverage policy and the 2026 Bridge
By Ran Chen#GLP-1#Medicare Part D#Payer Coverage